The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats
Autor: | Jennifer McGee, Vivian Fonseca, David B. Casey, Subramanyam N. Murthy, Rose-Claire St. Hilaire, Adeleke M. Badejo, Dennis B. McNamara, Philip J. Kadowitz |
---|---|
Rok vydání: | 2010 |
Předmět: |
Agonist
medicine.medical_specialty Intimal hyperplasia Nitric Oxide Synthase Type III medicine.drug_class Endocrinology Diabetes and Metabolism Type 2 diabetes Glucagon-Like Peptide-1 Receptor Eating Insulin resistance Diabetes mellitus Internal medicine Receptors Glucagon Internal Medicine medicine Animals Aorta Hyperplasia Venoms business.industry Transcription Factor RelA Balloon catheter medicine.disease Rats Rats Zucker Endocrinology Exenatide Female Blood sugar regulation Insulin Resistance Carotid Artery Injuries Peptides Tunica Intima Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | Diabetes and Vascular Disease Research. 7:138-144 |
ISSN: | 1752-8984 1479-1641 |
DOI: | 10.1177/1479164109360269 |
Popis: | We studied the effect of a synthetic GLP-1 receptor agonist, exenatide, a drug approved for the treatment of type 2 diabetes, on the recovery from vascular injury in Zucker (non-diabetic) fatty rats. Exenatide 5.0 µg/kg per day or saline was administered for seven days before, and 21 days after balloon catheter mediated carotid injury. A pair feeding experiment helped differentiate between the drug itself and the known effects of the drug on decreased food intake. Body weight and glucose (weekly), carotid artery I/M ratio, aortic protein eNOS and NFκB-p65 were measured. Body weight gain in exenatide rats was significantly lower (53±5 vs. 89±8 g) than controls. Blood glucose did not change significantly. The I/M ratio in the exenatide group was 0.2±0.1 vs. 0.9±0.1 in controls ( p |
Databáze: | OpenAIRE |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.